Natus Medical closes acquisition of Micromed

Natus Medical today announced it completed the previously announced acquisition of Micromed Holdings.

The deal, announced in December 2022, will add Micromed’s neurophysiology solutions to Natus Medical’s offerings. The financial details of the acquisition were not disclosed.

The Micromed acquisition is the first transaction made by the Middleton, Wisconsin-based company since its $1.2 billion acquisition by the ArchiMed group in July 2022.

“We are thrilled to complete this deal and move forward combining the Natus and Micromed teams and product portfolios,” Natus President Austin Noll said in a news release. “Together, we will be able to provide our neuroscience customers a more comprehensive product offering and unrivaled global service and support through the increased breadth and depth of our combined resources.”

Natus Medical has specialized in 85 years of neurodiagnostic leadership. Micromed’s portfo…

Read more
  • 0

Natus Medical to acquire Micromed

Natus Medical announced today that it entered into a definitive agreement to acquire neurophysiology solution provider Micromed.

Middleton, Wisconsin-based Natus expects the transaction to close in early 2023. The company elected to not disclose the financial terms for the deal. It marks the first transaction made by the company since its $1.2 billion acquisition by the ArchiMed group in July.

“We are pleased to make this first growth-oriented investment as an ArchiMed portfolio company,” said Thomas J. Sullivan, Natus CEO. “The breadth and depth of clinical expertise in Natus and Micromed will enable us to bring exciting innovation to our neuroscience customers and their patients around the globe.”

The company plans to join with Micromed to provide a best-in-class portfolio of neurodiagnostic and neuromonitoring solutions. Micromed’s offerings include Brain Quick, MyoQuick, NeuroWerk, SleepRT and Moberg. Natus expects those…

Read more
  • 0

ArchiMed completes $1.2B acquisition of Natus Medical

Natus Medical (Nasdaq:NTUS) announced today that ArchiMed’s investment firm completed its previously announced acquisition of the company.

In April, the company announced that the MED Platform II fund of ArchiMed — an investment firm focused on the healthcare industry — would acquire Natus, a developer of medical devices for screening, diagnosing and treating disorders affecting the brain, neural pathways, and eight sensory nervous systems, for a total equity value of $1.2 billion.

Under the terms of the acquisition, Natus shareholders received $33.50 in cash for each share of common stock, according to a news release.

“ArchiMed’s mix of operational, medical, scientific and financial expertise will help us continue our mission to serve our customers as we internationalize and grow our business,” Natus CEO Thomas J. Sullivan said in the release. “Our Natus teammates are excited to advance the standard of care and improve outcomes and quality o…

Read more
  • 0

Archimed Group to acquire Natus Medical for $1.2B

Natus Medical today announced that it entered a definitive agreement to be acquired by Archimed for a total equity value of $1.2 billion.

Through the agreement, Natus shareholders will receive $33.50 in cash for each share of Natus common stock to represent a 29% premium to the stock’s close price on April 14.

“The sale of Natus Medical to ArchiMed will provide our shareholders with immediate and substantial cash value, as well as a compelling premium, and the Board has unanimously agreed that this transaction is in the best interests of our shareholders,” Natus Medical Chairperson Joshua Levine said in an SEC filing.

Natus shareholders will receive $33.50 in cash for each share of the company’s common stock they own. The transaction is expected to close in the third quarter of 2022 and is subject to customary closing conditions and approval by Natus shareholders and regulatory approvals. According to the company, once the acquisition is comp…

Read more
  • 0

Natus Medical beats the Street in Q4, announces realignment of businesses

Natus Medical (NSDQ:NTUS) this week posted fourth-quarter results that beat the overall consensus on Wall Street.

The Pleasanton, California-based maker of monitoring and diagnostics for newborns reported profits of $1.7 million, or 5¢ per share, on sales of $128.7 million for the three months ended Dec. 31, 2021, for a bottom-line loss of 66.5% on sales growth of 8.37% compared with Q4 2020.

Adjusted to exclude one-time items, earnings per share were 47¢, 3¢ ahead of The Street, where analysts were looking for sales of $125.8 million.

“I would like to thank our Natus teammates for their efforts to deliver growth in both revenue and income in the fourth quarter despite challenges from both COVID and supply chain-related constraints,” president and CEO Thomas Sullivan said in a news release. “Throughout the year we focused on ensuring our products were available to clinicians and despite incurring over $1.7 million in higher costs in the fourth quarter al…

Read more
  • 0

Spectrum Plastics CEO is leaving to take over Natus Medical

Natus Medical’s incoming CEO Thomas Sullivan [Image from LinkedIn]

Natus Medical recently announced that it appointed Thomas Sullivan as president and CEO, effective December 27.

Sullivan previously served as president and CEO of medical device global contract manufacturer Spectrum Plastics. He has also held numerous leadership roles at A&E Medical, Symmetry Surgical and Symmetry Medical. In addition, he held executive positions at Johnson & Johnson, including president of J&J’s medical products Canada division and its U.S. orthopedics division.

Get the full story on MDO’s sister site MassDevice. 

Read more
  • 0

Natus Medical appoints new president and CEO

Natus Medical recently announced that it appointed Thomas Sullivan as president and CEO, effective Dec. 27.

Sullivan previously served as president and CEO of medical device global contract manufacturer Spectrum Plastics. He has also held numerous leadership roles at A&E Medical, Symmetry Surgical and Symmetry Medical. He held executive positions at Johnson & Johnson including president of J&J’s medical products Canaada division and its U.S. orthopedics division.

“We are thrilled to have Tom assume the leadership of Natus at this exciting time for our Company. He is a proven business leader with a long track record of success at creating shareholder value. As a Natus Independent Director these past three years, he has shown his strategic insight and drive for Natus’ potential for market leadership through holistic business model execution,” chairperson of the board Joshua Levine said in a news release. “The Board would like to thank Jonathan K…

Read more
  • 0